Skip to main content

Table 1 Analysis across 21 assessed variables

From: Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort

   # of patients % of patients Hazard ratio for overall survival (range) P-value
Gender Female 12 39 1  
Male 19 61 1.01 (0.24–4.30) 0.984
Race, ethnicity White, non-Hispanic 14 45 1  
White, Hispanic 8 26 1.65 (0.22–11.9) 0.372
Black, non-Hispanic 5 16 2.90 (0.40–20.9) 0.53
Black, Hispanic 2 6 3.08 (0.26–36.4) 0.29
Not specified 2 6   
ECOG performance status 0–1 20 65 1  
2 11 35 0.60 (0.12–3.01) 0.54
R-IPI Very good or good 13 42 1  
Poor 18 58 6.00 (0.74–48.9) 0.094
Disease stage 3 2 6 1  
4 29 94 High 0.999
Cell of origin Non-GCB 10 32 1  
GCB 10 32 1.41 (0.31–6.40) 0.295
Not specified 11 35   
Bulky disease Yes 15 48 1.79 (0.42–7.55) 0.426
Double expressor Yes 9 29 2.02 (0.48–8.49) 0.338
Triple expressor Yes 4 13 0.297 (0.036–2.44) 0.259
CNS involvement prior therapy Yes 2 6 1.26 (0–inf) 0.999
Prior therapy with RCHOP Yes 29 94 High 0.999
Prior autologous HSCT Yes 12 39 0.34 (0.06–1.80) 0.203
Age (c) 29–84 31 100 1.01 (0.956–1.08) 0.623
Ki67% (c) 40–99 29 94 1.02 (0.96–1.08) 0.499
  Not specified 2 6   
LDH at cell infusion (U/L) (c) 128–1248 31 100 1.00 (1.00–1.00) 0.003
LDH at cell infusion/100 (U/L) (c) 128–1248/100 31 100 1.34 (1.10–1.64) 0.003
LDH before lymphodepletion (U/L) (c) 120–1277 31 100 1.41 (1.15–1.72) 0.0008
LDH at disease recurrence (c) 123–1552 31 100 1.09 (0.92–1.27) 0.325
Number of metastatic sites (c) 0–6 31 100 1.18 (0.713–1.95) 0.522
CRS (c) 0–3 31 100 0.94 (0.38–2.32) 0.891
ICANS (c) 0–4 31 100 1.19 (0.71–2.00) 0.511
CARTOX (c) 0–10 31 100 0.88 (0.74–1.04) 0.140
Tocilizumab doses (c) 0–4 31 100 1.04 (0.58–1.88) 0.886
  1. Variables (c) were treated as continuous; remainder as categorical